Two different pills reduce the risk of ovarian cancer coming back after surgery and chemotherapy, according to studies presented at the annual meeting of the European Society for Medical Oncology in Barcelona Saturday.
The results represent a step forward in treating a cancer that is diagnosed in 28,000 women annually in the U.S. and kills 14,000 women a year. Currently, women are treated with surgery to remove their tumors, followed with a type of chemotherapy. But in 85% of cases, the cancer comes back.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
I am a recurrent ovarian cancer patient and would like a copy of the article without having to pay for a subscription if possible, please. Thank you.